Duramed Pharmaceuticals, Inc. Completes Acquisition Of FEI Company Women’s Health And ParaGard(R) IUD Product

WOODCLIFF LAKE, N.J., Nov. 10 /PRNewswire-FirstCall/ -- Duramed Pharmaceuticals, Inc., a subsidiary of Barr Pharmaceuticals, Inc. , today announced that it has completed the acquisition of FEI Women’s Health, LLC. The closing of the transaction follows the termination of the Federal Trade Commission’s review of the acquisition. FEI is the owner of ParaGard(R) T 380A (Intrauterine Copper Contraceptive) IUD, which is approved for continuous use for the prevention of pregnancy for up to 10 years. The definitive agreement under which Duramed would acquire FEI for $281.5 million was executed and announced on October 18, 2005.

Duramed intends to integrate the existing FEI 50-person Specialized Sales Force into Duramed’s recently expanded Specialty Sales Force, increasing that sales force to approximately 100 representatives. In addition to ParaGard(R), the Specialty Sales Force will detail Niaspan(R) and Advicor(R) under the Company’s agreements with Kos Pharmaceuticals, Inc., as well as the Company’s SEASONALE(R) extended-cycle oral contraceptive and Trexall(TM) products.

ParaGard(R) T 380A was approved in 1984 and has been marketed in the United States since 1988. ParaGard(R) is known as the Copper T Model TCu 380A outside the United States. ParaGard(R) is the only contraceptive approved for 10 years of continuous use and is more than 99% effective at preventing pregnancy.

Financial Impact

Excluding charges associated with the acquisition, including amortization charges related to an inventory write-up, Barr anticipates that the transaction will be neutral to earnings in fiscal 2006 and accretive for fiscal 2007 and thereafter.

Safety Information on ParaGard(R)

ParaGard(R) does not protect against HIV/AIDS or other sexually transmitted diseases. A woman must not use ParaGard(R) if she currently has acute Pelvic Inflammatory Disease (PID) or engages in current behavior suggesting a high risk for PID. ParaGard(R) is also not an option for women who might be pregnant, have had a post-pregnancy or post-abortion uterine infection in the past 3 months, have cancer of the uterus or cervix, have an infection in the cervix, have an allergy to any component of ParaGard(R), or have Wilson’s disease.

The most common side effects of ParaGard(R) are heavier and longer periods for a few months after placement; some women have spotting between periods. For most women, this typically subsides after a few months. If you ever miss a period, call your healthcare professional without delay, as you might be pregnant.

Some possible serious complications that have been associated with intrauterine contraceptives, including ParaGard(R), are pelvic inflammatory disease (PID), perforation of the uterus, and expulsion (where the contraceptive falls completely or partially out of the uterus).

Barr Pharmaceuticals, Inc. is a holding company whose principal subsidiaries, Barr Laboratories, Inc. and Duramed Pharmaceuticals, Inc., develop, manufacture and market generic and proprietary pharmaceuticals.

Forward-Looking Statements

Except for the historical information contained herein, the statements made in this press release constitute forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements can be identified by their use of words such as “expects,” “plans,” “projects,” “will,” “may,” “anticipates,” “believes,” “should,” “intends,” “estimates” and other words of similar meaning. Because such statements inherently involve risks and uncertainties that cannot be predicted or quantified, actual results may differ materially from those expressed or implied by such forward-looking statements depending upon a number of factors affecting the Company’s business. These factors include, among others: the difficulty in predicting the timing and outcome of legal proceedings, including patent-related matters such as patent challenge settlements and patent infringement cases; the outcome of litigation arising from challenging the validity or non- infringement of patents covering our products; the difficulty of predicting the timing of FDA approvals; court and FDA decisions on exclusivity periods; the ability of competitors to extend exclusivity periods for their products; our ability to complete product development activities in the timeframes and for the costs we expect; market and customer acceptance and demand for our pharmaceutical products; our dependence on revenues from significant customers; reimbursement policies of third party payors; our dependence on revenues from significant products; the use of estimates in the preparation of our financial statements; the impact of competitive products and pricing on products, including the launch of authorized generics; the ability to launch new products in the timeframes we expect; the availability of raw materials; the availability of any product we purchase and sell as a distributor; the regulatory environment; our exposure to product liability and other lawsuits and contingencies; the increasing cost of insurance and the availability of product liability insurance coverage; our timely and successful completion of strategic initiatives, including integrating companies and products we acquire and implementing our new enterprise resource planning system; fluctuations in operating results, including the effects on such results from spending for research and development, sales and marketing activities and patent challenge activities; the inherent uncertainty associated with financial projections; changes in generally accepted accounting principles; and other risks detailed from time-to-time in our filings with the Securities and Exchange Commission, including in our Annual Report on Form 10-K for the fiscal year ended June 30, 2005.

The forward-looking statements contained in this press release speak only as of the date the statement was made. The Company undertakes no obligation (nor does it intend) to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except to the extent required under applicable law.

Barr Pharmaceuticals, Inc.

CONTACT: Carol A. Cox of Barr Pharmaceuticals, Inc., +1-201-930-3720,ccox@barrlabs.com

MORE ON THIS TOPIC